Autolus Therapeutics (6A3A) Price & Analysis

3 Followers

6A3A Stock Chart & Stats

€2.06

€0.08(6.45%)

At close: Jul 24 4:00 PM EDT

€2.06

€0.08(6.45%)

Day’s Range― - ―

52-Week Range€1.04 - €2.16

Previous CloseN/A

Volume0.00

Average Volume (3M)10.00

Market Cap

€447.74M

Enterprise Value€590.54

Total Cash (Recent Filing)€201.63M

Total Debt (Recent Filing)€83.51M

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Oct 29, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding266,162,540

10 Day Avg. Volume10

30 Day Avg. Volume10

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)2.97

Price to Sales (P/S)7.01

P/FCF Ratio-1.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€6.65

Price Target Upside222.60% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.67

Revenue Forecast (FY)€128.35M

Bulls Say, Bears Say

Bulls Say

Commercial Revenue GrowthRapidly rising AUCATZYL revenue and higher full-year guidance indicate stronger commercial adoption and expanding demand. This provides a growing operating base for Autolus, supports investment in its pipeline, and may improve future earnings power as sales scale.

Gross-margin ImprovementThe sharp margin improvement suggests that higher volumes, operational efficiencies, and manufacturing progress are beginning to enhance product economics. If management reaches its mature margin target, incremental revenue could generate greater contribution toward operating expenses and reduce losses.

Commercial Footprint ExpansionA broader authorized-center network expands patient access and creates more channels for AUCATZYL utilization. Continued site additions in the U.S. and U.K. can support sustained commercial penetration, diversify revenue sources, and strengthen the infrastructure needed for future launches.

Bears Say

Persistent Operating LossesAutolus remains materially unprofitable even as revenue grows, showing that commercial scale has not yet covered the company’s operating base. Continued losses could delay self-funded growth, require additional capital, and make future profitability dependent on further execution and margin expansion.

Heavy Cash BurnSustained negative operating and free cash flow indicates that Autolus is consuming substantial liquidity while developing and commercializing its therapies. Unless revenue and margins improve materially, ongoing funding needs may constrain strategic flexibility and increase reliance on external financing.

Milestone-contingent FinancingA significant portion of expected financing is conditional on future commercial performance, so the planned liquidity runway is not fully secured. Missing milestones could reduce available capital while the company continues funding losses, clinical programs, and commercialization costs.

Autolus Therapeutics News

Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders

06:06 EDT Autolus Therapeutics (AUTL) files to sell 3.5M American Depositary Shares for holders Published first on TheFly...

2d ago

AUTL

Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel

Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene...

7d ago

AUTL

Autolus Therapeutics Earnings Call Highlights Growth Momentum

Autolus Therapeutics (($AUTL)) has held its Q2 earnings call. Read on for the main highlights of the call....

25d ago

AUTL

Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory

Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics and keeping the price target at...

1M ago

AUTL

Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge

Autolus Therapeutics ( ($AUTL) ) has shared an update. In the quarter ended June 30, 2026, Autolus Therapeutics...

1M ago

AUTL

Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M

Coonsensus $139.42M. The company said, “Autolus recently increased the full year 2026 guidance for AUCATZYL net product revenue...

1M ago

AUTL

Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)

Reports Q2 revenue $45.69M, consensus $40.15M. “In the second quarter we achieved substantial sales growth in the ongoing...

1M ago

AUTL

AUTL Upcoming Earnings Report: What to Expect?

Autolus Therapeutics (AUTL) is scheduled to report 2nd quarter earnings on 08/11/2026, before the market opens. Regarding Q2...

1M ago

AUTL

Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Autolus Therapeutics. The associated price target...

1M ago

AUTL

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility

Autolus Therapeutics ( ($AUTL) ) has issued an announcement. Autolus Therapeutics raised its full-year 2026 guidance for AUCATZYL...

1M ago

AUTL

Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M

“In the second quarter, AUCATZYL sales increased approximately 70% over Q1 2026 and more than 100% compared to...

1M ago

AUTL

Autolus Secures New $250 Million Financing and Warrants

Autolus Therapeutics ( ($AUTL) ) has provided an announcement. Autolus Therapeutics entered into a senior secured notes facility...

1M ago

AUTL

Autolus shareholders approve 2025 accounts and board slate

Autolus Therapeutics ( ($AUTL) ) just unveiled an announcement. On June 29, 2026, Autolus Therapeutics held its 2026...

3M ago

AUTL

Autolus Schedules 2026 AGM and Engages ADS Holders

Autolus Therapeutics ( ($AUTL) ) has shared an update. On June 5, 2026, Autolus Therapeutics published its UK...

3M ago

AUTL

6A3A FAQ

What was Autolus Therapeutics Plc’s price range in the past 12 months?

Autolus Therapeutics Plc lowest stock price was €1.04 and its highest was €2.16 in the past 12 months.

What is Autolus Therapeutics Plc’s market cap?

Autolus Therapeutics Plc’s market cap is €447.74M.

When is Autolus Therapeutics Plc’s upcoming earnings report date?

Autolus Therapeutics Plc’s upcoming earnings report date is Oct 29, 2026 which is in 43 days.

How were Autolus Therapeutics Plc’s earnings last quarter?

Autolus Therapeutics Plc released its earnings results on Aug 11, 2026. The company reported -€0.129 earnings per share for the quarter, beating the consensus estimate of -€0.167 by €0.038.

Is Autolus Therapeutics Plc overvalued?

According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Autolus Therapeutics Plc pay dividends?

Autolus Therapeutics Plc does not currently pay dividends.

What is Autolus Therapeutics Plc’s EPS estimate?

Autolus Therapeutics Plc’s EPS estimate is -0.14.

How many shares outstanding does Autolus Therapeutics Plc have?

Autolus Therapeutics Plc has 266,162,540 shares outstanding.

What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?

Autolus Therapeutics Plc reported an EPS of -€0.129 in its last earnings report, beating expectations of -€0.167. Following the earnings report the stock price went up 7.821%.

Which hedge fund is a major shareholder of Autolus Therapeutics Plc?

Currently, no hedge funds are holding shares in DE:6A3A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Autolus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.59%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Autolus Therapeutics Plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Autolus Therapeutics (6A3A) Earnings & Revenues

Historic Earnings Reports

6A3A Company Deck

6A3A Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.View all DE:6A3A earnings summaries

6A3A Stock 12 Month Forecast

Average Price Target

€6.65

▲(222.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.6306,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.645562,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.5100461538461536,3.0200923076923076,3.5301384615384617,4.040184615384615,4.550230769230769,5.060276923076923,5.570323076923077,6.0803692307692305,6.590415384615384,7.100461538461538,7.610507692307692,8.120553846153847,{"y":8.6306,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.357350923076923,2.7147018461538464,3.072052769230769,3.4294036923076923,3.7867546153846154,4.144105538461538,4.501456461538462,4.8588073846153845,5.216158307692307,5.573509230769231,5.930860153846154,6.288211076923076,{"y":6.645562,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.1781,2.3562,2.5343,2.7123999999999997,2.8905,3.0686,3.2466999999999997,3.4248,3.6029,3.7809999999999997,3.9591,4.1372,{"y":4.3153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.589,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.319,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >